Guaifenesin Has No Effect on Sputum Volume or Sputum Properties in Adolescents and Adults With Acute Respiratory Tract Infections

@article{HofferSchaefer2014GuaifenesinHN,
  title={Guaifenesin Has No Effect on Sputum Volume or Sputum Properties in Adolescents and Adults With Acute Respiratory Tract Infections},
  author={Agathe Hoffer-Schaefer and Henry J Rozycki and Melissa A Yopp and Bruce K. Rubin},
  journal={Respiratory Care},
  year={2014},
  volume={59},
  pages={631 - 636}
}
BACKGROUND: Guaifenesin (glyceryl guaiacolate ether [GGE]) has been studied as a cough suppressant and as an expectorant; however, published studies to date have failed to find a consistent benefit. METHODS: An 8-day multi-center clinical trial was conducted to study the effect of two 600-mg extended-release GGE tablets twice daily for 1 week on cold symptoms, sputum volume, and properties in adolescents and adults with productive cough from an acute respiratory tract infection (RTI). The study… 

Figures and Tables from this paper

Safety And Tolerability Of Extended-Release Guaifenesin In Patients With Cough, Thickened Mucus And Chest Congestion Associated With Upper Respiratory Tract Infection

TLDR
This study found that ER guaifenesin was well tolerated and had a favorable safety profile in otherwise healthy patients suffering from symptoms of cough, thickened mucus and chest congestion associated with URTI.

Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections

TLDR
Clinical pharmacology and patient studies support the clinical utility of guaifenesin in respiratory conditions where mucus hypersecretion is prevalent: acute upper respiratory tract infections (URTIs), stable chronic bronchitis, and possibly rhinosinusitis.

Can Big Data Analyses Help Speed Up the Clinical Development of Mucoactive Drugs for Symptomatic RTIs?

TLDR
Big Data analysis techniques may help overcome current clinical research limitations by identifying differentiating disease and patient factors to speed up the development process to substantiate the effectiveness of expectorant/mucoactive drugs in relieving RTI symptoms.

Secretion properties, clearance, and therapy in airway disease

  • B. Rubin
  • Medicine, Biology
    Translational Respiratory Medicine
  • 2014
TLDR
Chronic airway diseases like cystic fibrosis, chronic bronchitis, asthma, diffuse panbronchiolitis, and bronchiectasis are all associated with chronic inflammation and each are associated with the production of mucus and sputum with characteristic composition, polymer structure, and biophysical properties.

DHPS_A_222109 87..94

TLDR
This study found that ER guaifenesin was well tolerated and had a favorable safety profile in otherwise healthy patients suffering from symptoms of cough, thickened mucus and chest congestion associated with URTI.

Is Extended-Release Guaifenesin No Better Than a Placebo?

TLDR
The results of a double-blind randomized placebo-controlled trial examining the effects of guaifenesin on both the volume and physical properties of sputum in patients with acute respiratory tract infections (RTIs) are reported.

Rational use of mucoactive medications to treat pediatric airway disease

Clinical Practice Guidelines for Diagnosis and Management of Cough-Chinese Thoracic Society (CTS) Asthma Consortium.

TLDR
Cough is the most common symptom in respiratory specialist clinics of tertiary hospitals and outpatient clinics of primary health care facilities in China and is often misdiagnosed as chronic bronchitis or chronic pharyngitis.

The role of mucoactive agents in the mechanically ventilated patient: a review of the literature

TLDR
An extensive search was completed through PUBMED and CINAHL via EBSCO, along with the Cochran library to find all trials using mucoactive agents in the critically ill patient population and to determine their effect on clinical outcomes.

Aerosol Medications for Treatment of Mucus Clearance Disorders

  • B. Rubin
  • Medicine, Biology
    Respiratory Care
  • 2015
TLDR
The pathophysiology of secretory hyper-responsiveness and mucus hypersecretion is reviewed and the different aerosol medications that can be used to augment secretion clearance are discussed.

References

SHOWING 1-10 OF 20 REFERENCES

Antitussive effect of guaifenesin in young adults with natural colds. Objective and subjective assessment.

TLDR
The efficacy of guaifenesin in reducing cough frequency in young adults with acute respiratory disease was evaluated by both an objective cough counting system and a questionnaire, finding that the diurnal variation in cough frequency measured by the tape recording was not apparent from the subjective cough frequency estimates obtained by the questionnaire.

Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms

TLDR
Results from the clinical pilot and validation studies showed that the SUM8 diary scores were robust and reliable for use as efficacy endpoints in studies of mucoactive drugs.

Over-the-counter (OTC) medications for acute cough in children and adults in community settings.

TLDR
There is no good evidence for or against the effectiveness of OTC medicines in acute cough, with higher numbers of adverse effects in participants taking preparations containing antihistamines and dextromethorphan.

Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings.

TLDR
There is no good evidence for or against the effectiveness of OTC medicines in acute cough, and higher quality evidence is needed to determine the effective of self care treatments for acute cough.

Designing clinical trials to evaluate mucus clearance therapy.

TLDR
The challenges of designing a clinical trial to test the effectiveness of potentially mucoactive therapy can be met to advance knowledge and to develop truly effective therapy for mucus clearance disorders.

Cough suppressant and pharmacologic protussive therapy: ACCP evidence-based clinical practice guidelines.

TLDR
These findings suggest that suppressant therapy is most effective when used for the short-term reduction of coughing, and relatively few drugs are effective as cough suppressants.

An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant, and albuterol.

TLDR
These agents appear to have a minimal direct action on sputum in vitro, suggesting that at the concentrations studied, these agents do not have a significant beneficial effect on either the mucociliary transportability or CTR of chronic bronchitisSputum.

Mucolytics, expectorants, and mucokinetic medications.

  • B. Rubin
  • Biology, Medicine
    Respiratory care
  • 2007
TLDR
DNA-active medications such as dornase alfa (Pulmozyme) and potentially actin-depolymerizing drugs such as thymosin beta(4) may be of value in helping to break down airway pus.

The powerful placebo in cough studies?

  • R. Eccles
  • Medicine, Psychology
    Pulmonary pharmacology & therapeutics
  • 2002
TLDR
A model is proposed to explain the antitussive effects of placebo treatment on the basis of endogenous opioid neurotransmitters, which may explain the analgesic potency of opioid medicines such as morphine.

Effect of guaifenesin on mucin production, rheology, and mucociliary transport in differentiated human airway epithelial cells

TLDR
It is suggested that guaifenesin could improve mucociliary clearance in humans by reducing the release and/or production of mucins, thereby altering mucus rheology.